Month: April 2022

EssilorLuxottica: EssilorLuxottica and GrandVision complete the transaction with ORIG BENE for the sale of stores in the Netherlands and Belgium

Written by Customer Service on April 4, 2022. Posted in Mergers And Acquisitions.

EssilorLuxottica and GrandVision complete the transactionwith ORIG BENE for the sale of stores in the Netherlands and Belgium Charenton-le-Pont, France, Schiphol, the Netherlands and Graz, Austria (April 4, 2022 – 8:00 am) – EssilorLuxottica, GrandVision and the Optic Retail International Group BENE, a member of MPG Austria (“ORIG/MPG”), announced today that the companies have completed the transaction for ORIG/MPG to acquire 142 EyeWish stores in the Netherlands and 35 GrandOptical stores in Belgium. This follows the commitments agreed upon with the European Commission on March 23, 2021, as part of the acquisition of GrandVision by EssilorLuxottica. EssilorLuxottica, GrandVision and ORIG/MPG confirm that European Commission has approved the transaction.AttachmentDOWNLOAD PDF VERSION OF THE NEWS RELEASE

Proactive news headlines including Duke Exploration, Creso Pharma, Great Boulder Resources and Tempest Minerals

Written by Customer Service on April 4, 2022. Posted in Mergers And Acquisitions.

Sydney, April 04, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Duke Exploration Ltd (ASX:DEX) has delivered further encouraging copper grades from the final three holes of a five-hole diamond drilling program at Rogers prospect within the flagship Bundarra Project in Queensland. Click here Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) is moving to capitalise on opportunities presented by the ‘Marijuana Opportunity Reinvestment and Expungement’ (MORE) Act, which passed through the US House of Representatives on Friday, April 1, 2022, with 220 votes in favour and 204 against. Click here Great Boulder Resources Ltd (ASX:GBR) has enhanced the corporate and financial skillset of its board through the appointment of Karen O’Neill...

Virgin Coconut Oil Market to Worth USD 3.69 Billion by 2021-2028 | Virgin Coconut Oil Industry Striking CAGR of 7.35%

Written by Customer Service on April 4, 2022. Posted in Mergers And Acquisitions.

Companies covered in virgin coconut oil market are Edward & Sons Trading Co (California, U.S.), Greenville Agro Corporation (Cebu City, Philippines), The Coconut Company (UK) Ltd. (London, U.K.), Healthy Traditions, Inc. (Texas, U.S.), Nutiva Inc. (California, U.S.), The Hain Celestial Group (New York, U.S.), MaxCare VCO (Karnataka, India), Celebes Coconut Corporation (Butuan City, Philippines), SC Global Coco Products Inc. (Mandaluyong City, Philippines), Barlean’s (Washington, U.S.) and more players profiled. Pune, India, April 04, 2022 (GLOBE NEWSWIRE) — The global virgin coconut oil market size was USD 2.11 billion in 2020. The market is projected to grow from USD 2.24 billion 2021 to USD 3.69 billion in 2028 at a CAGR of 7.35% during the 2021-2028 period. This vital information is presented by Fortune Business Insights™,...

Unibail-Rodamco-Westfield to sell Gera Arcaden in Germany for €116 Mn

Written by Customer Service on April 4, 2022. Posted in Mergers And Acquisitions.

Paris, Amsterdam, April 4, 2022 Press release Unibail-Rodamco-Westfield to sell Gera Arcaden in Germany for €116 Mn Unibail-Rodamco-Westfield (URW) today announces an agreement with an institutional investor for the sale of Gera Arcaden, in Germany, for an agreed Total Acquisition Cost of €116 Mn (at 100%, URW share 51%), which represents a premium to the last appraised value. The transaction is expected to complete in Q2-2022, subject to standard closing conditions. Gera Arcaden is an 38,300 sqm shopping centre, including offices, located in the city centre of Gera. URW also entered into a management contract and will continue the asset and property management of the centre through its German third-party asset management business. For further information, please contact : Investor RelationsMaarten Otte+33 7 63 86 88 78Maarten.Otte@urw.com...

New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis

Written by Customer Service on April 4, 2022. Posted in Public Companies.

75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study 70% of patients with SPMS and PPMS demonstrated stable or improved cognition after one year of OCREVUS treatment in CONSONANCE Separate analysis on treatment disparities showed fewer Black and Hispanic patients with MS initiate high-efficacy treatments within two years of diagnosis Data at AAN support the body of evidence for OCREVUS more than 450,000 patient years and more than 225,000 patients treated globallyBasel, 04 April 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) data that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and...

Combined General Meeting of April 19, 2022: Availability of preparatory documents

Written by Customer Service on April 4, 2022. Posted in Public Companies.

Combined General Meeting of April 19, 2022: Availability of preparatory documents Paris, France, April 4, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that the prior notice of the Combined General Meeting containing the agenda, the draft resolutions presented by the Board of Directors for agreement by the shareholders was published in the BALO n°31 (Bulletin des Annonces Légales Obligatoires) on March 14, 2022 and the convening notice that was published in the BALO n°39 on April 1, 2022 as well as in the Affiches Parisiennes (legal newspapers). As of today the information regarding the Combined General Meeting mentioned in article R. 22-10-23...

Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

Written by Customer Service on April 4, 2022. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivityIntegrating Pharmaceuticals and Oncology business units into an Innovative Medicines (IM) business with separate US and International commercial organizations will increase focus, strengthen competitiveness and drive synergiesNew Strategy & Growth function combines corporate strategy, R&D portfolio strategy and business development to further strengthen pipeline with high-value medicines across internal and external opportunitiesNew Operations unit combines Novartis Technical Operations and Customer & Technology Solutions units to generate economies of scale, drive productivity and create a strong...

Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis

Written by Customer Service on April 4, 2022. Posted in Public Companies.

FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitisIf approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis There are approximately 160,000 patients in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatmentsParis and Tarrytown, N.Y., April 4, 2022. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow. The...

The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

Written by Customer Service on April 4, 2022. Posted in Public Companies.

Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings. The pivotal studies in Japanese patients supported the approval of Pivlaz™ (clazosentan) in Japan in January 2022, Pivlaz is expected to be available in April 2022.Allschwil, Switzerland – April 4, 2022Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals Japan today announce the publication of “Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients” in the Journal of Neurosurgery1. Clazosentan, a selective endothelin A (ETA) receptor antagonist, significantly reduced the combined incidence of...

U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults

Written by Customer Service on April 4, 2022. Posted in Public Companies.

If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patients Since the beginning of the pandemic, more than one million people hospitalised with COVID-19 have been treated with Actemra/RoActemra worldwide1 Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European Union Roche has established a comprehensive access approach to improve availability of Actemra/RoActemra around the worldBasel, 04 April 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and has granted Priority Review for Actemra®/RoActemra® (tocilizumab) intravenous for the treatment of COVID-19 in hospitalised adults...

Month: April 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals